Delivery Order SPE2DB22D2214-SPE2DB25FS6AZ
Award Date 8/6/25
Potential Completion Date 8/7/25
Potential Value $45K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,432.61 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 16, 2025, with completion expected by December 17, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine used for immunization of adult populations, representing part...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,209.05 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed price, competitively awarded contract with no set-aside designation. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization of adults 18 years of age and older. The contract was awarded on December 17, 2025, with an ultimate completion date of December 18, 2025, and will be performed at AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes. The contract is a firm fixed price delivery order with no set-aside designation, executed on May 27, 2025, with an ultimate completion date of May 28, 2025. Performance will occur at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing the type...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $90,302.96 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 22, 2025, with completion expected by September 23, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the awardee's Conshohocken, Pennsylvania headquarters. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, reflecting the Department of...
- The Defense Logistics Agency awarded a delivery order valued at $40,921.90 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on November 7, 2025, with completion targeted for November 10, 2025. This firm fixed-price delivery order, placed without set-aside designation, represents a competitive award under the company's larger pharmaceutical supply vehicle with DLA. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,173.57 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 18, 2025, with completion scheduled for December 19, 2025. This competitively awarded, firm fixed-price contract requires performance at AmerisourceBergen's Conshohocken, Pennsylvania location. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing a critical pharmaceutical commodity for military...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, valued at $10,347.75 under a firm fixed-price contract. This non-set-aside delivery order was awarded on December 2, 2025, with an ultimate completion date of December 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 and older,...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B vaccine (20 mcg/0.5 mL syringe) on July 21, 2025, with completion scheduled for July 22, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,057.16 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on October 15, 2025, with completion scheduled for October 16, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract covers the supply of HEPLISAV-B, a recombinant hepatitis B vaccine, which...
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...